|
 |
Aktuelle Praxis der Lipidapherese- Heibges A, Fassbender C, Klingel R. Nieren- und Hochdruckkrankheiten 39: 322-337, 2010.
- Efficacy criteria and cholesterol targets for LDL apheresis
- Thompson GR, HEART-UK LDL Apheresis Working Group. Atherosclerosis 208: 317-321, 2010.
- Recommendations for the use of LDL apheresis
- Thompson GR, Barbir M, Davies D, Dobral P, Gesinde M, Livingston M, Mandry P, Marais AD, Matthews S, Neuwirth C, Pottle A, le Roux C, Scullard D, Tyler C, Watkins S. Atherosclerosis 198: 247-255, 2008.
- Dextran-sulfate-adsorption of atherosclerotic lipoproteins from whole blood or separated plasma for lipid-apheresis - comparison of performance characteristics with DALI and Lipidfiltration
- Julius U, Parhofer KG, Heibges A, Kurz S, Klingel R. Geiss HC. Journal of Clinical Apheresis 22: 215-223, 2007.
- Whole blood adsorption systems Liposorber DL and DALI for LDL apheresis: Intraindividual comparison of performance characteristics
- Julius U, Heibges A, Kurz S, Klingel R. Poster, Kongress für Nephrologie, Saarbrücken, 2005.
- Lipidfiltration - safe and effective methodology to perform lipid apheresis
- Klingel R, Mausfeld P, Fassbender C, Goehlen B. Transfusion and Apheresis Science 30: 245-254, 2004.
- From Membrane Differential Filtration to lipidfiltration - technological progress in LDL-apheresis.
- Klingel R, Faßbender T, Fassbender C, Goehlen B. Therapeutic Apheresis & Dialysis 7: 350-358, 2003.
- Differential indication of lipoprotein apheresis during pregnancy
- Klingel R, Göhlen B, Schwarting A et al.. Therapeutic Apheresis & Dialysis 7/3: 359-364, 2003.
- Fortschritte der Lipidapherese am Beispiel der Membran-Differential-Filtration / Lipidfiltration
- Klingel R, Goehlen B, Fassbender C et al.. Lipidreport 11: 12-17, 2002.
- Intraindividual comparison of two extracorporeal LDL apheresis methods: lipidfiltration and HELP
- Julius U, Metzler W, Pietzsch J, Klingel R. Int J Art Org 25: 1180-1188, 2002.
Lipoprotein(a)
- Lipidapherese bei isolierter Lipoprotein(a)-Erhöhung mit progredienter Gefäßerkrankung
- Klingel R. Herzmedizin 26: 136-139, 2009.
- Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events
- Jaeger BR, Richter Y, Nagel D, Heigl F, Vogt A, Roeseler E, Parhofer K, Ramlow W, Koch M, Utermann G, Labarrere CA, Seidel D, for the Group of Clinical Investigators. Nature Clinical Practice - Cardiovascular Medicine 6: 229-239, 2009.
- Lipoprotein(a) erhöht das Infarktrisiko -Ergebnisse der Copenhagen City Heart Studie
- Hucko T, Graf K. Kardiologe 2: 112-113, 2008.
- Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population - The Copenhagen City Heart Study
- Kamstrup PR, Benn M, Tybjaerg-Hansen A, Nordestgaard BG. Circulation 117: 176-184, 2008.
- Maximale Korrektur eines Risikofaktors - Bei isolierter Lipoprotein(a)-Erhöhung und fortschreitender Gefäßerkrankung ist die Lipidapherese eine Leistung der gesetzlichen Krankenkassen
- Klingel R, Deutsches Ärzteblatt 105: A1496, 2008.
- Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes - Prospective results from the Bruneck Study
- Kiechl S, Willeit J, Mayr M, Viehweider B, Oberhollenzer M, Kronenberg F, Wiedermann CJ, Oberthaler S, Xu Q, Witztum JL, Tsimikas S. Arteroscler Thromb Vasc Biol 27: 1788-1795, 2007.
- Conditional risk factors for atherosclerosis
- Kullo IJ, Ballantyne, CM. Mayo Clin Proc 80: 219-230, 2005.
